Peptide Analog Stability via N-Terminal Acetylation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current peptide therapies for diabetes, such as INGAP-PP and HIP, have limitations due to their short plasma half-life and the need for high doses, which restricts their clinical applications in treating diabetes and other diseases associated with impaired pancreatic function.
Innovation Solution
Development of peptide analogs with improved stability and activity compared to the wild-type peptides, including modifications like acetylated N-terminus, amidated C-terminus, and fatty acid modifications, which can be administered at lower doses and exhibit enhanced pharmacokinetic properties for treating diabetes and other conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If INGAP-PP or HIP peptides are used to treat diabetes, then islet neogenesis and insulin secretion are improved, but plasma half-life is short and high doses are required
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of the peptide through N-terminal acetylation, C-terminal amidation, and incorporation of non-natural amino acids. These structural modifications change the physical and chemical parameters of the peptide, resulting in improved plasma stability and extended half-life while maintaining the biological activity required for islet neogenesis.
Solution Approach 2:
The patent creates composite peptide structures by combining natural amino acids with non-natural amino acids (such as N-methylated amino acids or amino acids with hydrophobic side chains). This composite approach enhances the peptide's resistance to proteolytic degradation while preserving its ability to induce islet neogenesis, effectively resolving the contradiction between stability and activity.
2Reliability
If high doses of INGAP-PP or HIP are administered, then therapeutic effect is achieved, but clinical applicability is limited due to side effects and cost
Solution Approach 1:
By modifying peptide parameters through chemical modifications (acetylation, amidation, non-natural amino acid incorporation), the patent increases the peptide's bioavailability and pharmacokinetic properties. This allows achieving the same therapeutic effect at lower doses, reducing both the quantity of substance required and associated costs.
Solution Approach 2:
The patent develops peptide analogs that are more stable and longer-lasting in circulation. This effectively replaces the need for frequent high-dose administrations with lower-dose, less frequent dosing regimens, reducing the overall quantity of peptide substance required for treatment.
3Duration of action of moving object
If peptide modifications are made to extend half-life, then plasma stability is improved, but molecular complexity increases
Solution Approach 1:
The patent employs targeted parameter changes by making specific, well-defined modifications (acetylation at N-terminus, amidation at C-terminus, substitution with 1-3 non-natural amino acids). These controlled modifications extend half-life without creating excessive molecular complexity, as each modification serves a specific function in enhancing stability or pharmacokinetic properties.
Data Source
Figure 1~2
Figure 3~4
Figure 5~6A
AI summary
Provided herein are peptides and analogs of INGAP and HIP peptides and modifications thereof. Also provided herein are said peptides, analogs or modifications thereof for use in methods of treating various diseases and conditions including impaired pancreatic function and metabolic diseases, for example, diabetes (types 1 and 2). The uses also include islets induction, expansion and proliferation for transplantation, promoting neuroprotection or nerve regeneration, promoting liver regeneration or inhibition inflammation.